Drug Trial Radar · NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
952
Planned (sponsor's estimate)
Start
Dec 7, 2022
Primary completion
Dec 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Oct 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Conditions
- High Grade Epithelial Ovarian Cancer
- High Grade Serous Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
- Mesothelioma
- Breast Adenocarcinoma
- Triple Negative Breast Cancer
- Hormone Receptor-positive/Her2 Negative Breast Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Platinum Sensitive Ovarian Cancer (PSOC)
- Primary Refractory Ovarian Cancer
- Uterine Cancer
- Cervical Cancer
Interventions
Rina-SDrug
Intravenous infusion of Rina-S
CarboplatinDrug
Carboplatin intravenous infusion
BevacizumabDrug
Bevacizumab intravenous infusion
PembrolizumabDrug
Pembrolizumab intravenous infusion
ErythromycinDrug
Erythromycin oral administration
ItraconazoleDrug
Itraconazole oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]Time frame: Through end of treatment, up to approximately 1 year.
- Parts A, and D - Number of Participants with Dose Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Parts C, E, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C and F) or Investigator (Part E, G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Through end of treatment, up to approximately 1 year.
- Part K (US Participants Only) - Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Findings by HolterTime frame: Cycles 1 to 3 (each cycle is 21 days)
- Part L - Peak Plasma Concentration (Cmax) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
- Part L - Area Under the Plasma Concentration Versus Time Curve (AUC) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
Locations
67 sites in 4 countries. Site status is shown where the registry gives one.
USOR HonorHealth
Phoenix, Arizona · Recruiting
USOR Arizona Oncology Associates
Tucson, Arizona · Recruiting
University of California Los Angeles Medical Center
Los Angeles, California · Recruiting
University of California, San Diego; Moores Cancer Center
San Diego, California · Recruiting
USOR Sansum Clinic
Santa Barbara, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
USOR Florida Cancer Specialists South
Fort Myers, Florida · Recruiting
USOR Florida Cancer Specialists North
St. Petersburg, Florida · Recruiting
USOR Florida Cancer Specialists East
West Palm Beach, Florida · Recruiting
Augusta University Georgia Cancer Center
Augusta, Georgia · Recruiting
University of Kansas Medical Center (KUMC)
Westwood, Kansas · Recruiting
USOR Maryland Oncology Hematology
Rockville, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
USOR Minnesota Oncology Hematology
Maplewood, Minnesota · Recruiting
MD Anderson Cancer Center at Cooper- Two Cooper Plaza
Camden, New Jersey · Recruiting
Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
University of Oklahoma - Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
USOR Oncology Associates of Oregon, P.C.
Eugene, Oregon · Recruiting
Compass Oncology - Rose Quarter
Portland, Oregon · Recruiting
USOR Alliance Cancer Specialist
Doylestown, Pennsylvania · Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
Women and Infants Hospital of Rhode Island
Providence, Rhode Island · Recruiting
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
USOR Texas Oncology
Abilene, Texas · Recruiting
Texas Oncology - Central / South Texas
Austin, Texas · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
USOR Texas Oncology
Fort Worth, Texas · Recruiting
Texas Oncology - Northeast TX
Tyler, Texas · Recruiting
USOR Texas Oncology Gulf Coast
Woodland, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
USOR Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
USOR Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Swedish Cancer Institute
Everett, Washington · Recruiting
Cancer hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fujian, China, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangdong, China, China · Recruiting
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.